FAS position on a risk-sharing pilot project

Implementing the pilot project of the Ministry of health Care without taking into consideration FAS comments can have adverse consequences for the budgetary system, failure to reach the goals of medicine supplies to the population and competition restriction

In 2017 a pilot project may be launched in Russia when financial burden for supplying “Abirateron” medicinal drug to the patients will be split between drug suppliers and the health care authorities of the Russian Federation (risk-sharing).

The pilot project is designed by the Ministry of Health Care to modernize the drug provision system to particular categories of the population, implementing rational pricing models, particularly, based on reference prices for drugs under the frame of No. 136-r Order of the Government of the Russian Federation of 30.01.2015.

Having analyzed the documents outlining the pilot project conditions, FAS concluded that basing the project on the conditions proposed by the Ministry of Health Care will not allow achieving the target goals.

With an example of the pilot project for supplying “Abirateron” medicinal drug to the patients, FAS proposed the Ministry of Health Care a different approach to the criteria, conditions and mechanisms of pilot projects.

Head of FAS Department for Control over Social Sphere and Trade, Timophey Nizhegorodtsev informed: “Employing the pilot project without taking into account FAS comments may cause adverse effects for the budgetary system, prevent control over drug therapy efficiency, inability to reach the pilot project targets on drug supply for the population and competition restriction on the relevant markets”.